AC
FOLD

Ascend Capital’s Amicus Therapeutics FOLD Stock Holding History

Ascend Capital’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-176,492
Closed -$2.65M – 193
2018
Q1 		$2.65M Buy
+176,492
New +$2.69M 0.11% 150
2017
Q4 		– Sell
-252,522
Closed -$3.81M – 227
2017
Q3 		$3.81M Buy
+252,522
New +$3.34M 0.14% 115

Other funds holding FOLD

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ascend Capital's FOLD Position: Q2 2018 in Review

Ascend Capital sold out of Amicus Therapeutics (FOLD) in Q2 2018, closing a stake of 176,492 shares — an estimated $2.65M sold.

Ascend Capital first reported a position in FOLD in Q3 2017 and held it in 2 quarters. The position peaked at $3.81M in Q3 2017. 200 funds tracked by Wall St. Rank hold FOLD as of Q2 2018.

  • Ascend Capital reported no remaining Amicus Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Ascend Capital sold 176,492 Amicus Therapeutics shares in Q2 2018, an estimated $2.65M.
  • Ascend Capital first reported a position in Amicus Therapeutics in Q3 2017 and held it in 2 quarters.
  • Ascend Capital's Amicus Therapeutics position peaked at $3.81M in Q3 2017.
  • 200 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q2 2018.

Based on Ascend Capital's 13F filing for Q2 2018, filed 13 Aug 2018.